| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 |
Form 4: Erdogan-Trinkaus Ipek, Chief Commercial Officer
Received 3,500 shares by exercise or conversion ($54.1K) · Sold 3,500 shares ($236K) |
| 10 Nov 2026 |
Form 4: Casamento Charles J, Director
Received 80,555 shares by exercise or conversion ($438K) · Sold 80,555 shares ($5.35M) |
| 10 Nov 2026 | 144 |
| 10 Nov 2026 | 144 |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
DEER PARK, Ill., November 5, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ... |
| 05 Nov 2026 |
8-K: Other Events
Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability |
| 02 Nov 2026 |
8-K: Other Events
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms |
| 14 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film |
| 06 Oct 2026 |
Form 4: Krempa David, Chief Business Officer
Received 10,522 shares by exercise or conversion · Sold 4,166 shares ($229K) |
| 06 Oct 2026 | 144 |
| 28 Sep 2026 |
8-K: Other Events
Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States |
| 31 Aug 2026 |
Form 4/A: Maier Paul V, Director
Received 62,500 shares by exercise or conversion ($280K) · Sold 50,000 shares ($2.95M) · Acquired 12,500 Employee Stock Option (Option Exercise/Conversion) |
| 28 Aug 2026 |
Form 4: Maier Paul V, Director
Received 50,000 shares by exercise or conversion ($189K) · Sold 50,000 shares ($2.95M) |
| 28 Aug 2026 | 144 |
| 24 Aug 2026 |
Form 4: Krempa David, Chief Business Officer
Received 25,000 shares by exercise or conversion ($183K) · Sold 25,000 shares ($1.63M) |
| 24 Aug 2026 | 144 |
| 20 Aug 2026 |
Form 4: Brynjelsen Sean, Director
Sold 8,978 shares ($562K) · Sold 91,022 shares ($5.53M) |
Loading...